Valbiotis SA

As of December 31, 2025, Valbiotis SA carries a market capitalization of 16.42M, placing it among publicly traded companies globally. Its enterprise value stands at 12.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valbiotis SA's next confirmed earnings release is scheduled for March 17, 2027.

As of December 31, 2025, Valbiotis SA has 24.06M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Valbiotis SA maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Valbiotis SA's stock has declined approximately 24.32% over the past 52 weeks. The 50-day moving average sits at 0.72, while the 200-day moving average is 0.88.

As of December 31, 2025, Valbiotis SA holds 8.68M in cash and equivalents against 5.09M in total debt, resulting in a net debt position of -4.74M. Total book value stands at 6.96M, with working capital of 7.73M providing operational flexibility.

Valbiotis SA's most recent stock split took place on June 10, 2026 with a 178:181 split ratio.